耳鼻咽喉科・頭頸部外科96巻11号

2024年10月発行

特集 頭頸部がん薬物療法—プロに学ぶ最善の選択

《唾液腺がんに対する薬物療法》

NTRK融合遺伝子陽性分泌癌

著者： 本間義崇¹

所属機関： ¹国立がん研究センター中央病院頭頸部・食道内科

ページ範囲：P.955 - P.958

文献概要

POINT

●唾液腺から発生する分泌癌は，数あるがん種のなかで最もNTRK融合遺伝子が検出される腫瘍である。

●根治的治療の適応がない病態の場合には，がん遺伝子パネル検査にてNTRK融合遺伝子を確認し，きわめて高い抗腫瘍効果を有するTRK阻害薬を適用することが，患者アウトカムの向上に重要である。

参考文献

gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open 1：e000023, 2016

2）Thiele CJ, et al：On Trk—the TrkB signal transduction pathway is an increasingly important target in cancer biology. Clin Cancer Res 15：5962-5967, 2009

3）Loewenthal N, et al：Nerve growth factor-tyrosine kinase A pathway is involved in thermoregulation and adaptation to stress：studies on patients with hereditary sensory and autonomic neuropathy type IV. Pediatr Res 57：587-590, 2005

4）Inoue K, et al：Runx3 is essential for the target-specific axon pathfinding of trkc-expressing dorsal root ganglion neurons. Blood Cells Mol Dis 30：157-160, 2003

Fusion Proteins. Clin Cancer Res 24：5807-5814, 2018

6）Solomon JP, et al：NTRK fusion detection across multiple assays and 33,997 cases：diagnostic implications and pitfalls. Mod Pathol 33：38-46, 2020

7）Iwaki S, et al：Comprehensive genomic profiling of salivary gland carcinoma：Analysis of the Center for Cancer Genomics and Advanced Therapeutics database in Japan. Int J Cancer 155：871-882, 2024

8）中外製薬株式会社：ロズリートレクカプセル．医薬品インタビューフォーム．https://chugai-pharm.jp/content/dam/chugai/product/roz/cap/if/doc/ros_if.pdf.

9）Demetri GD, et al：Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors. Clin Cancer Res 28：1302-1312, 2022

10）Desai AV, et al：Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations（STARTRK-NG）. Neuro Oncol 24：1776-1789, 2022

11）Drilon A, et al：Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 378：731-739, 2018

12）Laetsch TW, et al：Larotrectinib for paediatric solid tumors harbouring NTRK gene fusions：a multicenter, open-label, phase 1 study. Lancet Oncol 19：705-714, 2018

13）Le X, et al：Larotrectinib treatment for patients with TRK fusion-positive salivary gland cancers. Oncologist 29：e779-e788, 2022

14）Waguespack SG, et al：Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid cancer. Eur J Endocrinol 186：631-643, 2022

15）Yokota T, et al：Real-world experience of tropomyosin receptor kinase inhibition with entrectinib in ETV6-NTRK3 positive metastatic salivary secretory carcinoma：A case series. Head Neck 45：E10-E15, 2023

16）Harada G, et al：TRK inhibitor activity and resistance in TRK fusion-positive cancers in adalts. Cancer Genet 264-265：33-39, 2022

17）Florou V, et al：Clinical activity of selitrectinib in a patient with mammary analogue secretory carcinoma of the parotid gland with secondary resistance to entrectinib. J Natl Compr Canc Netw 19：478-482, 2021